Home › Compare › PSTTF vs JNJ

PSTTF vs JNJ: Dividend Comparison 2026

PSTTF yields 1379.31% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSTTF wins by $327926178.92M in total portfolio value
10 years
PSTTF
PSTTF
● Live price
1379.31%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$327926178.94M
Annual income
$286,995,341,463,684.70
Full PSTTF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PSTTF vs JNJ

📍 PSTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSTTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSTTF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PSTTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSTTF
Annual income on $10K today (after 15% tax)
$117,241.38/yr
After 10yr DRIP, annual income (after tax)
$243,946,040,244,131.97/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, PSTTF beats the other by $243,946,040,243,428.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSTTF + JNJ for your $10,000?

PSTTF: 50%JNJ: 50%
100% JNJ50/50100% PSTTF
Portfolio after 10yr
$163963089.48M
Annual income
$143,497,670,732,256.22/yr
Blended yield
87.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PSTTF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSTTF buys
0
JNJ buys
0
No recent congressional trades found for PSTTF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSTTFJNJ
Forward yield1379.31% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$327926178.94M ✓$20.0K
Annual income after 10y$286,995,341,463,684.70 ✓$827.78
Total dividends collected$324920394.51M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSTTF vs JNJ ($10,000, DRIP)

YearPSTTF PortfolioPSTTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$148,631$137,931.03$10,676$355.77+$138.0K → PSTTF
2$2,075,001$1,915,965.64$11,407$389.39+$2.06M → PSTTF
3$27,218,680$24,998,428.97$12,198$426.53+$27.21M → PSTTF
4$335,586,754$306,462,766.83$13,056$467.62+$335.57M → PSTTF
5$3,890,354,077$3,531,276,249.42$13,987$513.12+$3890.34M → PSTTF
6$42,421,557,343$38,258,878,480.81$14,998$563.56+$42421.54M → PSTTF
7$435,284,512,667$389,893,446,310.20$16,098$619.52+$435284.50M → PSTTF
8$4,204,696,744,549$3,738,942,315,995.26$17,295$681.69+$4204696.73M → PSTTF
9$38,253,119,134,080$33,754,093,617,412.28$18,599$750.82+$38253119.12M → PSTTF
10$327,926,178,937,150$286,995,341,463,684.70$20,022$827.78+$327926178.92M → PSTTF

PSTTF vs JNJ: Complete Analysis 2026

PSTTF — Stock

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Full PSTTF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PSTTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSTTF vs SCHDPSTTF vs JEPIPSTTF vs OPSTTF vs KOPSTTF vs MAINPSTTF vs ABBVPSTTF vs MRKPSTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.